Document:

EXHIBIT 10.1

EXECUTION COPY

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.

AMENDMENT
TO

CROSS-LICENSE AGREEMENT

THIS AMENDMENT TO CROSS-LICENSE AGREEMENT
(the “Amendment”) is made as of April
25th, 2007 (the “Amendment Effective Date”) between Pfizer
Inc, a Delaware corporation having an office at 235 East 42nd Street, New York,
New York 10017, and its Affiliates (“Pfizer”),
and Medarex, Inc., a New Jersey corporation with a business address at 707
State Road, Princeton, New Jersey 08540 (“Medarex”).  Pfizer and Medarex each may be referred to
herein individually as a “Party”
or collectively as the “Parties.”

RECITALS

A.   Pfizer and Medarex entered into a
Cross-License Agreement dated September 15, 2004 (the “Cross-License
Agreement”).

B.   The Parties now wish to amend the Cross-License
Agreement to include certain additional patent claims and Patents.

NOW,
THEREFORE, in consideration of the foregoing premises and for
other good and valuable consideration, the receipt and sufficiency of which are
acknowledged, the Parties, intending to be legally bound, do hereby agree as
follows:

1.             The definition of
Covered Patent is deleted and replaced with the following new definition:

“Covered
Patent” means any Patent to the extent that it claims (a) an
Antibody, or a group of Antibodies, or the Exploitation of such Antibody or
group of Antibodies, (b) a composition, whether alone or in combination with an
article of manufacture, comprising one or more Antibodies or the Exploitation
of such a composition, (c) a nucleic acid sequence or host cell that
specifically codes for, incorporates, expresses or secretes an Antibody, (d)
the use of such a nucleic acid sequence or host cell to make (including to
manufacture, formulate, purify, express, recover and secrete) an Antibody, (e)
a method of making (including manufacturing, formulating, purifying,
expressing, recovering, and secreting) (i) an Antibody, (ii) a composition
comprising one or more Antibodies or (iii) CTLA-4; (f) a method of using
an Antibody or a composition comprising one or more Antibodies; or (g) CTLA-4.

For the avoidance of doubt, the following language has been deleted
from the definition: “Covered Patents shall not include any Patents to the
extent that they claim any method of manufacturing Licensed Products.”

[ * ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 1
 

2.             Schedule A, Medarex
Patents and Patent Applications, is deleted and replaced with the attached
Schedule A.

3.             Schedule B, Pfizer
Patents and Patent Applications, is deleted and replaced with the attached
Schedule B.

4.             The definitions of
Medarex Patents and Pfizer Patents are amended to read as follows:

“Medarex Patents” means (a) all Covered
Patents Controlled by Medarex (other than through a license from Bristol-Myers
Squibb Company (“BMS”)) or its Affiliates as of the
Amendment Effective Date that would be infringed (and with respect to Patent
applications, would be infringed after issuance) by the Exploitation of a
Pfizer Product in the absence of the license grant set forth in Section 2.1.2,
including the Patents set forth in Schedule A hereto, and (b) all
Covered Patents Controlled by Medarex or its Affiliates (other than through a
license from BMS) that are filed either from such Covered Patents in clause (a)
above or from an application claiming priority therefrom to the extent of
claims not directed to new matter, but in each case ((a) and (b)) excluding any
Medarex Excluded Patents.

“Pfizer Patents” means (a) all Covered
Patents Controlled by Pfizer or its Affiliates as of the Amendment Effective
Date that would be infringed (and with respect to Patent applications, would be
infringed after issuance) by the Exploitation of a Medarex Product in the
absence of the license grant set forth in Section 2.1.1, including the Patents
set forth in Schedule B hereto, and (b) all Covered Patents Controlled
by Pfizer or its Affiliates that are filed either from such Covered Patents in
clause (a) above or from an application claiming priority therefrom to the
extent of claims not directed to new matter, but in each case ((a) and (b))
excluding any Pfizer Excluded Patents.

5.             The definition of Medarex
Excluded Patents and Pfizer Excluded Patents are amended to read as follows:

“Medarex
Excluded Patents” means (a) Mice-Related Patents, (b) Allison
Patents, and (c) claims of any Patents that Medarex or any of its Affiliates
own, have under license or otherwise Control to the extent that they (i)  claim (A) one or more particular Antibodies where such
particular Antibody(ies) is specifically defined by the amino acid sequence of
CDR 1, 2 and 3 of either the heavy or the light chain variable region of such
Antibody(ies) (each such specifically defined Antibody being a “Particular Antibody”) or the Exploitation of such Particular
Antibody(ies), (B) a composition comprising one or more such Particular
Antibodies or the Exploitation of such a composition, (C) a nucleic acid sequence
or host cell that specifically codes for, incorporates, expresses or secretes one
or more Particular Antibodies, (D) the use of a nucleic acid sequence, host
cell or other composition of matter to make (including to manufacture,
formulate, purify, express, recover and secrete) one or more Particular Antibodies,
(E) a method of making (including manufacturing, formulating, purifying,
expressing, recovering, and secreting) one or more Particular Antibodies or a
composition comprising such Particular Antibody(ies), or (F) a method of using one
or more Particular Antibodies or a composition comprising such Particular
Antibody(ies), or  (ii) validly claim priority to a 

[ * ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 2
 

Patent filed on or
before September 15, 2004 and claim one or more Particular Antibodies, whether
specifically or generally, together with, or otherwise in combination with, a
specific therapeutic or prophylactic composition of matter, whether in a fixed
dosage form or as a combination therapy, wherein the composition of matter is
recited in the claim by a specific name, specific compositional description,
specific protein structure or specific chemical structure, or the Exploitation
of the foregoing, or (iii) validly claim priority to a Patent filed after
September 15, 2004 and claim one or more Antibodies, whether specifically or
generally, together with, or otherwise in combination with, one or more
antibodies (other than an Antibody) or fragment(s) thereof, whether in a fixed
dosage form or as a combination therapy, or the Exploitation of the foregoing.  Without limiting the foregoing, Medarex
Excluded Patents shall include any Patents to the extent that they claim or
cover [ * ].

“Pfizer
Excluded Patents” means claims of any Patents that Pfizer or
any of its Affiliates own, have under license or otherwise Control to the
extent that they (a)  claim (i) one
or more Particular Antibodies, or the Exploitation of such Particular Antibody(ies),
(ii) a composition comprising one or more Particular Antibodies or the
Exploitation of such a composition, (iii) a nucleic acid sequence or host cell
that specifically codes for, incorporates, expresses or secretes one or more
Particular Antibodies, (iv) the use of a nucleic acid sequence or host cell or
other composition of matter to make (including to manufacture, formulate,
purify, express, recover and secrete) one or more Particular Antibodies, (v) a
method of making (including manufacturing, formulating, purifying, expressing,
recovering, and secreting) one or more Particular Antibodies or a composition
comprising such Particular Antibody(ies), or (vi) a method of using one or more
Particular Antibodies or a composition comprising such Particular Antibody(ies),  or (b) validly claim priority to a Patent filed on or
before September 15, 2004 and claim one or more Particular Antibodies, whether
specifically or generally, together with, or otherwise in combination with, a
specific therapeutic or prophylactic composition of matter, whether in a fixed
dosage form or as a combination therapy, wherein the composition of matter is
recited in the claim by a specific name, specific compositional description,
specific protein structure or specific chemical structure, or the Exploitation
of the foregoing, or (c) validly claim priority to a Patent filed after
September 15, 2004 and claim one or more Antibodies, whether specifically or
generally, together with, or otherwise in combination with, one or more
antibodies (other than an Antibody) or fragment(s) thereof, whether in a fixed
dosage form or as a combination therapy, or the Exploitation of the foregoing.  Without limiting the foregoing, Pfizer
Excluded Patents shall include any Patents to the extent that they claim or
cover [ * ] including claims that validly
claim priority to [ * ].

6.             Section 2.1.1 is
amended to add the following sentence at the end of the Section: “Nor does
anything in this Agreement provide rights to Medarex or any of its Affiliates
or Sublicensees/Licensees to use any tangible quantities of biological
materials developed by, or on behalf of, Pfizer.”

7.             Section 2.1.2 is
amended to add the following sentence at the end of the Section: “Nor does
anything in this Agreement provide rights to Pfizer or any of its Affiliates or

[ * ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 3
 

Sublicensees/Licensees to
use any tangible quantities of biological materials developed by, or on behalf
of, Medarex.”

8.             Section 3.1(h) is
amended to read as follows:

“; and (h) as of the
Effective Date, to the best of Pfizer’s knowledge,  Schedule
B hereto lists Covered Patents owned or controlled by Pfizer or
its Affiliates and neither Pfizer nor its Affiliates has any agreement or
arrangement with a Third Party with respect to any Covered Patents that affects
its Control of the Pfizer Patents or would otherwise adversely affect Medarex’s
rights with respect to such Covered Patents under this Agreement.”

9.             Section 3.2(h) is
amended to read as follows:

“; and (h) as of the
Effective Date, to the best of Medarex’s knowledge, Schedule
A hereto lists Covered Patents owned or controlled by Medarex or
its Affiliates and neither Medarex nor its Affiliates has any agreement or
arrangement with a Third Party with respect to any Covered Patents that affects
its Control of the Medarex Patents or would otherwise adversely affect Pfizer’s
rights with respect to such Covered Patents under this Agreement.”

10.           For purposes of this
Amendment, the representations, warranties and covenants of the Parties in
Sections 3.1 and 3.2 are made again as of the Amendment Effective Date.  Further, Medarex represents and warrants to
Pfizer as of the Amendment Effective Date that, to Medarex’s knowledge, neither
Medarex nor any of its Affiliates owns or Controls any Patents (other than the
Medarex Patents and other than Patents obtained by a license from BMS) that
would be infringed (or, with respect to Patent applications, would be infringed
after issuance) by the Exploitation of a Pfizer Product and Pfizer represents
and warrants to Medarex as of the Amendment Effective Date that, to Pfizer’s
knowledge, neither Pfizer nor any of its Affiliates owns or Controls any
Patents (other than the Pfizer Patents) that would be infringed (or, with
respect to Patent applications, would be infringed after issuance) by the
Exploitation of a Medarex Product.

11.           This Amendment to
Cross-License Agreement shall not take effect unless and until BMS and Pfizer
shall have concurrently executed that certain License Agreement covering
certain BMS CTLA4 intellectual property.  Pfizer shall promptly notify Medarex in
writing when the License Agreement is executed. 

12.           This Amendment amends
the terms of the Cross-License Agreement and is deemed incorporated into, and
governed by all other terms of, the Cross-License Agreement.  Except as expressly amended hereby, the
Cross-License Agreement is not amended, modified or affected by this Amendment,
and the Cross-License Agreement and the rights and obligations of the Parties
thereunder remain in full force and effect in all respects.

13.           All capitalized terms
used but not defined in this Amendment shall have the meanings ascribed to them
in the Cross-License Agreement.

[ * ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 4
 

14.           This Amendment may be executed in any number of counterparts, each of
which shall be deemed an original but all of which together shall constitute
one and the same instrument.

[Signature Page Follows]

[ * ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 5
 

IN WITNESS
WHEREOF, duly-authorized representatives of the Parties have signed this Amendment
to Cross-License Agreement as a document under seal as of the Amendment Effective
Date.

	
  MEDAREX,
  INC.

  	
   

  	
  PFIZER INC

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By: 

  	
  /s/ Ronald
  Pepin, Ph.D.

  	
   

  	
   

  	
  By: 

  	
  /s/ John DeYoung

  	
   

  
	
   

  	
   

  	
   

  
	
  Name: Ronald Pepin, Ph.D.

  	
   

  	
  Name: John DeYoung

  
	
   

  	
   

  	
   

  
	
  Title: Senior
  Vice President,

  	
   

  	
  Title: Attorney-in-Fact

  
	
   

  	
   

  	
   

  
	
  Business
  Development

  	
   

  	
   

  
							

[ * ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 6
 

Schedule
A

Medarex
Patents and Patent Applications

[ * ]

[ * ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 7
 

Schedule
B

Pfizer
Patents and Patent Applications

Note:
The Patents marked with an asterisk on this Schedule B are owned jointly by
Pfizer,  Inc. and Abgenix, Inc.

[ * ]

*U.S. Patent No.
6,682,736

Issued: January
27, 2004

Titled: “Human
Monoclonal Antibodies to CTLA-4”

Inventors: Douglas
Charles HANSON, Mark Joseph NEVEU, Eileen Elliott MUELLER,           

Jeffrey Herbert HANKE, Steven Christopher GILMAN, C. Geoffrey DAVIS, and Jose 

Ramon CORVALAN

Assignee: Abgenix,
Inc. (Fremont, CA) and Pfizer, Inc. (New York, NY)

U.S.S.N.
09/472,087 filed on December 23, 1999

Claiming priority
from U.S.S.N. 60/113,647

[ * ]

[ * ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 8EXHIBIT
10.2

Execution
Version

[
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

AMENDMENT NO. 1

TO

COLLABORATION AND CO-PROMOTION AGREEMENT

THIS AGREEMENT (“Amendment”)  is made and
entered into effective as of April 25, 2007 (the “Amendment
Effective Date”) by and between Medarex, Inc., a New Jersey
corporation having its principal place of business at 707 State Road,
Princeton, New Jersey 08540-1437 (“Medarex”)
and Bristol-Myers Squibb Company, a Delaware corporation headquartered at
345 Park Avenue, New York, New York 10154 (“BMS”),
and amends the COLLABORATION AND CO-PROMOTION AGREEMENT (the
“Agreement”) made as of November
7, 2004 between Medarex and BMS.  Medarex
and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

WHEREAS, Medarex entered into that certain
Cross-License Agreement with Pfizer Inc. (“Pfizer”) dated
as of September 15, 2004 (the “Cross License”);

WHEREAS, Medarex desires that BMS assist it
in facilitating, and BMS is willing to help facilitate, an amendment of certain
terms and conditions under the Cross License; and

WHEREAS, Medarex and BMS both desire to enter into an
agreement with Pfizer to address certain issues related to the orphan drug
status of their respective products as contemplated by Section 10.5.1(c) of the
Agreement;

WHEREAS, concurrently with the execution of
this Amendment, BMS is entering into certain agreements with Pfizer such that
Pfizer is willing (a) to amend the Cross License in a manner that is acceptable
to Medarex and (b) to enter into an agreement with Medarex and BMS to address
those certain orphan drug issues in a manner acceptable to Medarex and BMS.

NOW, THEREFORE, in consideration of
the foregoing premises and the mutual covenants contained herein and other good
and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties, intending to be legally bound, agree as follows:

1.             The first
sentence of Section 6.4.1 is deleted in its entirety and replaced with the
following:

“Subject to
Sections 3.8.3, 5.3, 5.5.6, 6.4.2, 6.4.3, 6.4.4 and 6.5, with respect to each
Product for which Medarex exercises the Co-Promotion Option, (a) 

Medarex shall
receive forty-five percent (45%) of all Profits, and bear forty-five
percent (45%) of all Losses, as applicable, with respect to a Co-Promotion
Product in the United States, and (b) BMS shall receive fifty-five
percent (55%) of all Profits, and bear fifty-five percent (55%) of all
Losses, as applicable, with respect to such Co-Promotion Product in the
United States.”

2.             A new Section
6.4.4 is added to the Agreement, as follows:

“6.4.4               BMS Co-Promotion
Royalty.  With respect to each
Product for which Medarex exercises a Co-Promotion Option, BMS shall be
entitled to retain or receive a royalty equal to [ * ] of the Net Sales of such Product in the United States in
each Year during the Co-Promotion Term for such Product (the “BMS Co-Promotion Royalty”).  Any due and payable BMS Co-Promotion Royalty
shall be calculated and paid in accordance with Section 6.5.  For clarity, termination of the Co-Promotion
Term for a Product shall not relieve Medarex of its obligation to pay any BMS
Co-Promotion Royalties that have accrued prior to, but are unpaid as of, the
end of the Co-Promotion Term for such Product.”

3.             Section 6.5 is
deleted in its entirety and replaced with the following:

“6.5          Calculation
and Payment of Profit or Loss Share.

6.5.1       Reports and Payments in
General.  In the event that Medarex
exercises its Co-Promotion Option with respect to a Co-Promotion Product, each
Party shall report to the other Party, within twenty (20) days after the end of
each Quarter following such Exercise Notice, with regard to Net Sales and
Allowable Expenses incurred by such Party for such Co-Promotion Product during
such Quarter in the United States in a manner sufficient to enable the other
Party to comply with its reporting requirements; provided
that in the case of the first Quarter for which such report is due, each Party
shall additionally report all Allowable Expenses incurred by such Party prior
to such Quarter with respect to such Co-Promotion Product.  Such report shall specify in reasonable
detail Net Sales, all deductions allowed in the calculation of such Net Sales
and all expenses included in Allowable Expenses, and, if requested by a Party,
any invoices or other supporting documentation for any payments to a Third
Party that individually exceed fifty thousand Dollars ($50,000) (or such other
amount approved by the JFC) shall be promptly provided.  Within forty-five (45) days after the
end of each Quarter (or for the last Quarter in a Year, sixty (60) days after
the end of such Quarter), the Parties shall reconcile all Net Sales and
Allowable Expenses to ascertain whether there is a Profit or Loss (which
calculation shall be made without taking into account any BMS Co-Promotion
Royalty) and payments shall be made as set forth in subsections (a) and (b)
below, as applicable.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 2
 

a.     If there is a Profit for
such Quarter, then BMS shall (i) reimburse Medarex for Allowable Expenses
incurred by Medarex in such Quarter and (ii) pay to Medarex, subject to Section
6.4.2, an amount equal to forty-five percent (45%) of the Profit for such
Quarter, less the applicable aggregate BMS Co-Promotion Royalty for such
Quarter, provided that if Medarex’s share of the
Profit for such Quarter is less than the BMS Co-Promotion Royalty payable to
BMS, Medarex shall make a reconciling payment to BMS (either by direct payment
to BMS or by offset of other amounts payable by BMS to Medarex for such
Quarter) equal to the applicable shortfall within (A) such applicable
forty-five (45)-day period or sixty (60)-day period as set forth above or (B)
ten (10) Business Days after BMS has notified Medarex in writing of the amount
of the shortfall, whichever is the later date.

b.     If there is a Loss for
such Quarter, then (i) the Party that has borne less than its share of the
Allowable Expenses in such Quarter shall make a reconciling payment to the
other Party to assure that each Party bears its share of such Allowable
Expenses during such Quarter and (ii) Medarex shall make a reconciling payment
to BMS (either by direct payment to BMS or by offset of other amounts payable
by BMS to Medarex for such Quarter) equal to the aggregate BMS Co-Promotion
Royalty payable to BMS for such Quarter.

6.5.2           Last Calendar Quarter.  No separate payment shall be made for the
last Quarter in any Year.  Instead, at
the end of each such Year, a final reconciliation shall be conducted by
comparing the share of Profit or Loss to which a Party is otherwise entitled
for such Year pursuant to Sections 6.4 and 6.5 against the sum of all amounts
(if any) previously paid or retained by such Party for prior Quarters during
such Year, and the Parties shall make reconciling payments to one another no
later than ninety (90) days after the end of such Quarter, if and as necessary
to ensure that (i) each Party receives for such year its share of Profits and
bears its share of Losses in accordance with Sections 6.4.1 and 6.4.3, as
applicable, and (ii) BMS receives its full BMS Co-Promotion Royalty due and
payable for such Year.”

4.             Section 6.6 of
the Agreement is deleted in its entirety and replaced with the following:

“6.6     Royalties to Medarex.  In partial consideration of the license
rights granted by Medarex to BMS hereunder, subject to Sections 3.8 and 6.7,
BMS shall pay to Medarex royalties on (i) each Non-Co-Promoted Product sold in 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 3
 

the United
States and (ii) each Product and MDX-1379 sold in the Royalty Territory, on the
terms and conditions set forth in this Section 6.6.

6.6.1       United States.  Subject to Section 6.7.3:

a.         BMS shall pay Medarex
a royalty on Net Sales aggregated across all Non-Co-Promoted Products sold in
the United States in a given Year equal to:

i.      For that portion of
aggregate Net Sales of Non-Co-Promoted Products in a Year that is less than or
equal to [ * ] of such aggregate
Net Sales, provided that to the extent that some or
all of the Net Sales of such Non-Co-Promoted Products in such territory were
for use in Indications (A) with respect to which Medarex Opted-Out pursuant to
Section 3.8.2) and (B) for which Initial Approval has been obtained in such
territory (collectively, the “Opt-Out NP
Indications”), then, in such event BMS’ royalty obligation under
this Section 6.6.1(a)(i) shall be reduced to [
* ] on such Net Sales thereafter from such Non-Co-Promoted Products
that are attributable to such Opt-Out NP Indications;

ii.     For that portion of aggregate
Net Sales of Non-Co-Promoted Products in a Year that is more than [ * ] of such aggregate Net Sales, provided that to the extent that some or all of the Net
Sales of such Non-Co-Promoted Products in such territory were for Opt-Out NP
Indications, then, in such event BMS’ royalty obligation under this Section
6.6.1(a)(ii) shall be reduced to [ * ]
on such Net Sales thereafter from such Non-Co-Promoted Products that are
attributable to such Opt-Out NP Indications; and

iii.    For
that portion of aggregate Net Sales of Non-Co-Promoted Products in a Year that
is more than [ * ] of such
aggregate Net Sales, provided that
to the extent that some or all of the Net Sales of such Non-Co-Promoted
Products in such territory were for Opt-Out NP Indications, then, in such event
BMS’ royalty obligation under this Section 6.6.1(a)(iii) shall be reduced to [ * ] on such Net Sales thereafter from
such Non-Co-Promoted Products that are attributable to such Opt-Out NP
Indications.

b.         In the event that
there are Opt-Out NP Indications and 6.6.1(a)(ii) or (iii) applies for a given
Year, then the total royalty paid to Medarex under Section 6.6.1 shall be based
on a weighted average of Net Sales attributable to the Opt-Out NP Indications
and those attributable to other Indications. 
By way of example, if the total Net Sales for Non-Co-Promoted Products
in a Year is [ * ] and if [ * ] of such amount represents Net Sales
for use in Opt-Out NP Indications, then the total royalty payable to Medarex
for such Year shall be [ * ].  Net Sales attributable to the Opt-Out NP
Indications shall be determined as the Parties, through the JCC or JEC, may
agree or, in the event the JCC and the JEC are not able to agree, as an Expert
shall 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 4
 

determine as set forth in Section 16.2 following compliance with
Sections 2.7.3(c) and 16.1.1.

6.6.2       Japan.  BMS
shall pay Medarex a royalty on annual Net Sales aggregated across all Products
and MDX-1379 sold in Japan in a given Year equal to:

a.         [ * ];

b.         [ * ]; and

c.         [
* ].

6.6.3       Rest of the
World.  BMS shall pay Medarex a royalty on
annual Net Sales aggregated across all Products and MDX-1379 sold in the
Royalty Territory (other than Japan) in a given Year equal to:

a.         [ * ];

b.         [ * ]; and

c.         [ * ].

6.6.4       Proration. 
The royalty thresholds set forth in this Section 6.6 shall not be
pro-rated for any partial calendar Years, except for the last year of the
Royalty Term with respect to a given Product or MDX-1379, as applicable.”

5.             The last two
sentences of Section 6.7.1(a) are deleted in their entireties and replaced with the
following:

“If, for example,
sales for a Generic Product in a given year in France are greater than [ * ], but less than or equal to [ * ], of the sum of the entire market in
France, the royalty reduction for France will be subject to clause (B) above
and calculated as follows:  If total net
sales in France equal [ * ] and
total net sales in the Royalty Territory (other than Japan) equal [ * ] in a given year, the weighted average
royalty for the Royalty Territory (other than Japan), will be calculated as
follows:  [ * ].  Thus, the total
royalty reduction in the Royalty Territory (other than Japan) is calculated as
follows:  [ * ].”

6.             Notwithstanding
anything to the contrary, Sections 1, 2, 3, 4 and 5 of this Amendment shall be
effective, on a Product-by-Product and country-by-country basis, only for so
long as the manufacture (including formulating, purifying, expressing, recovering,
and secreting), use, or sale of a Product would infringe, but for the license
granted from Pfizer to Medarex under the Cross License, any Valid Claim of a
Pfizer Manufacturing Patent (defined below), including a Product manufactured
in a country where such 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 5
 

manufacture would
infringe, but for the license from Pfizer to Medarex under the Cross License,
such Valid Claim, even though such Product may be sold in a country where such
Product is not covered by such Valid Claim. 
For purposes of this Amendment, “Pfizer Manufacturing Patent” means any
patent Controlled by Pfizer or its Affiliates licensed to Medarex under the
Cross License, as amended, that claims any methods of making (including
manufacturing, formulating, purifying, expressing, recovering, and secreting),
or that claims any nucleic acid sequence, host cell, or other composition of
matter used for making (including manufacturing, formulating, purifying,
expressing, recovering, and secreting), including [ * ],
and any foreign equivalents thereof.

7.             BMS hereby
consents, in accordance with Section 6.7.3(a) of the Agreement, to Medarex’s
amendment of the Cross License, effective as of the Amendment Effective
Date, in the
form attached hereto as Exhibit A to this Amendment.

8.             Each
Party hereby represents and warrants to the other Party, as of the Amendment
Effective Date, that:

(i)            it
has full corporate power and authority under the laws of the state or country
of its incorporation to enter into this Amendment and to carry out the
provisions hereunder, and the individual signing below on its behalf is fully
authorized to do so by all requisite corporate action;

(ii)           it
has secured or obtained all necessary consents and approvals of all
governmental authorities, Regulatory Authorities and other Persons required to
be obtained by it to enter into and to perform this Amendment;

(iii)          this Amendment is a legal and valid
obligation binding upon it and is enforceable in accordance with its terms; and

(iv)          the
execution, delivery and performance of this Amendment by it does not conflict
with any agreement, oral or written, to which it is a party or by which it may
be bound, nor violate any law, decree or regulation of any court by which it
may be bound.

9.             This
Amendment amends the terms of the Agreement and is deemed incorporated into,
and governed by all other terms of, the Agreement.  Except as expressly amended hereby, the
Agreement is not amended, modified or affected by this Amendment, and the
Agreement and the rights and obligations of the Parties thereunder remain in
full force and effect in all respects.

10.          All
capitalized terms used but not defined in this Amendment shall have the
meanings ascribed to them in the Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 6
 

11.          The
provisions set forth in Article 17 of the Agreement are hereby incorporated by
reference herein as if such provisions were fully set forth in this Amendment.

{The next
page is the signature page.}

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 7
 

IN WITNESS WHEREOF, the Parties have executed this
Amendment in duplicate originals by their proper officers.

	
  Bristol-Myers Squibb
  Company 

  	
   

  	
  Medarex, Inc. 

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Elliott
  Sigal, M.D., Ph.D. 

  	
   

  	
   

  	
  By: 

  	
  /s/ Ronald Pepin, Ph.D. 

  	
   

  
	
   

  	
   

  	
   

  
	
  Title: Executive
  Vice President and Chief 

  Scientific Officer, Research and 

  Development

  	
   

  	
  Title: Senior Vice President, Business 

  Development

  
							

 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 8
 

EXHIBIT A

Form of
Amendment to Medarex-Pfizer Cross-License

{This Exhibit A
has been filed separately as an exhibit to the Registrant’s Quarterly 

Report on Form 10-Q for the period ended June 30, 2007, in executed form.}

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]